Literature DB >> 6334047

The effect of alterations in haematocrit on tumour sensitivity to X-rays.

D G Hirst, J L Hazlehurst, J M Brown.   

Abstract

Hypoxic cells in human tumours probably contribute to the failure of radiotherapy in some sites. Changes in the oxygen carrying capacity of the blood, such as in anaemia, have been shown to influence tumour response. The effect of acute and chronic changes in haematocrit on the radiosensitivity of three mouse tumours (EMT6, KHT and RIF-1) were studied. Alterations in haematocrit were achieved by bleeding followed by retransfusion. When radiation was preceded immediately by an acute reduction in haematocrit (anaemia), radiosensitivity was markedly reduced in each tumour. An acute rise in haematocrit (polycythaemia) increased or decreased X-ray sensitivity depending on its severity. The optimum haematocrit for maximum sensitivity was always found to be at a level 5-10 per cent above normal. When the time between induction of anaemia and irradiation was increased, simulating a progressively longer duration of anaemia, marked changes in radiosensitivity of all the tumours were observed. A short duration of anaemia resulted in a resistant tumour with each cell line, but the resistance was gradually lost as the anaemia was prolonged, even though no recovery in haematocrit occurred. The rate of recovery to normal radiosensitivity varied from 24 to 72 hours in the different tumours. Therefore, only haematocrit changes which occurred within 1-3 days of a dose of radiation affect the radiosensitivity of these tumours.

Entities:  

Mesh:

Year:  1984        PMID: 6334047     DOI: 10.1080/09553008414551521

Source DB:  PubMed          Journal:  Int J Radiat Biol Relat Stud Phys Chem Med        ISSN: 0020-7616


  9 in total

Review 1.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

Review 2.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

4.  Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

Authors:  Gillian Thomas; Shamshad Ali; Frank J P Hoebers; Kathleen M Darcy; William H Rodgers; Malti Patel; Ovardia Abulafia; Joseph A Lucci; Adrian C Begg
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

5.  Cinnarizine and flunarizine improve the tumour radiosensitisation induced by erythrocyte transfusion in anaemic mice.

Authors:  P J Wood; D G Hirst
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

6.  The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

Authors:  B Joiner; V K Hirst; S R McKeown; J J McAleer; D G Hirst
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

7.  Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate.

Authors:  D G Hirst; V K Hirst; B Joiner; V Prise; K M Shaffi
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

8.  The influence of haemoglobin affinity for oxygen on tumour radiosensitivity.

Authors:  D G Hirst; P J Wood
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

9.  Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

Authors:  O Thews; R Koenig; D K Kelleher; J Kutzner; P Vaupel
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.